July 01, 2023
On July 1, 2023 the U.S. Food and Drug Administration approved HADLIMA (adalimumab-bwwd), a tumor necrosis factor (TNF) blocker from Samsung Bioepis. [1]
HADLIMA is a biosimilar to Humira and is indicated for psoriatic arthritis (PsA) and plaque psoriasis, as well as uveitis, a common comorbidity of PsA. [1]
HADLIMA does not carry an interchangeable designation. It is given by injection. It is the fourth biosimilar to Humira to receive FDA approval. [1]
